Figure S5

A

Concentration (µg/mL) vs. Phagocytosed tumor cells (%)

B

EC_{50} all donors - ADCP for HT-29 - panitumumab

C

Fold enhancement all donors - ADCP for HT-29 - panitumumab

D

Concentration (µg/mL) vs. Phagocytosed tumor cells (%)

E

EC_{50} all donors - ADCP for HT-29 - cetuximab

F

Fold enhancement all donors - ADCP for HT-29 - cetuximab